Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05185739
Title Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC) (PRIMER-1)
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University College, London
Indications

hepatocellular carcinoma

Therapies

Lenvatinib + Pembrolizumab

Lenvatinib

Pembrolizumab

Age Groups: adult | senior
Covered Countries


No variant requirements are available.